protein intake optimization glp-1 receptor agonists Neurobiological Mechanisms and Therapeutic Potential of Glucagon-like Peptide-1 in Binge Eating Disorder: A Narrative Review Frontiers | GLP−1 receptor agonists

Description

Despite the valuable insights gained from this scoping review, several limitations should be acknowledged

When used along with lifestyle changes, you may expect to lose 5-10% of your body weight

As weight loss research progresses, and the potential for semaglutide drugs widens into more use casespossibly even treatments for alcohol or drug addiction, as NPR reported in October, citing the journal Addictionsome companies are betting that more consumers will seek supplements to optimize GLP-1 medication effectiveness, promote natural production of the GLP-1 hormone and manage the drugs negative symptoms

Kontraindikationen Bei folgenden Erkrankungen ist die Einnahme von GLP-1-Rezeptoragonisten kontraindiziert: Diabetes mellitus Typ 1 oder diabetische Ketoazidose Niereninsuffizienz Akute Pankreatitis Diabetische Gastroparese Alternativen Als alternative Antidiabetika knnen folgende Wirkstoffklassen eingesetzt werden: Insulin(e) Biguanide (Metformin) Sulfonylharnstoffe/Glinide DPP-4-Inhibitoren (Gliptine) SGLT-2-Inhibitoren (Gliflozine) -Glucosidase-Hemmer Hinweise Hypoglykmie Patienten, die einen GLP-1-Rezeptoragonisten in Kombination mit Sulfonylharnstoffen/Gliniden oder Insulin erhalten, knnen ein erhhtes Risiko fr Hypoglykmien haben